The FDA’s go-ahead comes after studies showed “significant responses” among patients treated with this therapy, according to Pfizer.
It further indicates that study data show that patients receiving four or more lines of other prior therapies achieved an overall response rate of 58% after using Elrexfio, with an estimated 82% maintaining response for at least nine months.
Multiple myeloma is an aggressive and currently incurable blood cancer that develops in the bone marrow.
The statement warns that the most common side effects of therapy with this drug are cytokine release syndromefatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and fever.
